{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:00:55Z","timestamp":1783018855152,"version":"3.54.6"},"reference-count":15,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,3,30]]},"abstract":"<jats:p>Cutaneous lymphangitis carcinomatosa (CLC) is a rare form of cutaneous metastasis that causes lymphoedema and various eruptions. We report a case of lung cancer with CLC that caused both superior vena cava (SVC) stenosis and cervicofacial oedema, suggestive of SVC syndrome. A 64-year-old woman with lung adenocarcinoma presented with cervicofacial oedema and erythema, followed by severe dyspnoea 2 months after four cycles of carboplatin, pemetrexed and bevacizumab triplet therapy. Although chest CT indicated SVC stenosis, cervicofacial oedema remained despite treating the SVC stenosis via balloon dilation. A skin biopsy of the erythematic sample confirmed CLC as the cause of the patient\u2019s symptoms. CLC should be considered as a differential diagnosis of cervicofacial oedema in addition to SVC syndrome, especially when it is observed in combination with skin erythema and induration. Moreover, a skin biopsy should be performed promptly for accurate diagnosis of CLC and to decide on appropriate treatment.<\/jats:p>","DOI":"10.1136\/bcr-2018-224206","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T17:25:42Z","timestamp":1524158742000},"page":"bcr-2018-224206","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Cutaneous lymphangitis carcinomatosa made cervicofacial oedema intractable in a patient with superior vena cava syndrome"],"prefix":"10.1136","volume":"2018","author":[{"given":"Eriko","family":"Kashihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-3317","authenticated-orcid":false,"given":"Osamu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Mio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.1","doi-asserted-by":"crossref","unstructured":"Straka C , Ying J , Kong FM , et al . Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. Springerplus 2016;5.doi:10.1186\/s40064-016-1900-7","DOI":"10.1186\/s40064-016-1900-7"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jaad.2007.01.034","article-title":"Cutaneous infiltration by cancer","volume":"57","author":"Marcoval","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2354.2009.01102.x","article-title":"Cancer-related secondary lymphoedema due to cutaneous lymphangitis carcinomatosa: clinical presentations and review of literature","volume":"19","author":"Damstra","year":"2010","journal-title":"Eur J Cancer Care"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/tbj.12738","article-title":"Blue Lymphangitis of the Breast after Breast Cancer: Case Report","volume":"23","author":"Arfi","year":"2017","journal-title":"Breast J"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.0303-6987.2004.00207.x"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/gyno.2002.6808","article-title":"Skin relapse from cervical cancer","volume":"87","author":"Palaia","year":"2002","journal-title":"Gynecol Oncol"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.7","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.35.459"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.lungcan.2012.09.009","article-title":"Cutaneous lymphangitis carcinomatosa in a patient with lung adenocarcinoma: case report and literature review","volume":"79","author":"Prat","year":"2013","journal-title":"Lung Cancer"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.9","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70173-Q"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.10","doi-asserted-by":"crossref","unstructured":"Kobayashi K , Nakachi I , Naoki K , et al . Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis. Clin Lung Cancer 2018.doi:10.1016\/j.cllc.2018.01.001","DOI":"10.1016\/j.cllc.2018.01.001"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.11","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1468-3083.2010.03818.x","article-title":"Cutaneous metastasis of lung carcinoma: a retrospective study of 12 cases","volume":"25","author":"Dhambri","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1440-0960.2011.00828.x","article-title":"Cutaneous metastasis from lung cancer: retrospective analysis of 30 patients","volume":"53","author":"Marcoval","year":"2012","journal-title":"Australas J Dermatol"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.14","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-Positive advanced non-small-cell lung cancer: AURA Study Phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025042703263040000_2018.apr19_1.bcr-2018-224206.15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-224206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:26:44Z","timestamp":1745749604000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-224206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":15,"alternative-id":["10.1136\/bcr-2018-224206"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-224206","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,19]]}}}